M&T Bank Corp Exelixis, Inc. Transaction History

M&T Bank Corp

$30.1 Billion
Q3 2024

A detailed history of M&T Bank Corp transactions in Exelixis, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 14,433 shares of EXEL stock, worth $513,959. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,433

Previous 14,433 -0.0%

Holding current value

$513,959

Previous $374,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$21.96 - $27.6 $35,597 - $44,739	1,621 Added 12.65%	14,433 $374,000
Q2 2024 Jul 31, 2024	BUY	$20.34 - $23.73 $22,068 - $25,747	1,085 Added 9.25%	12,812 $287,000
Q1 2024 May 07, 2024	SELL	$20.17 - $23.93 $4,981 - $5,910	-247 Reduced 2.06%	11,727 $278,000
Q4 2023 Feb 06, 2024	BUY	$19.25 - $24.13 $17,748 - $22,247	922 Added 8.34%	11,974 $287,000
Q3 2023 Nov 02, 2023	BUY	$19.04 - $22.74 $2,303 - $2,751	121 Added 1.11%	11,052 $241,000
Q2 2023 Aug 09, 2023	SELL	$18.17 - $20.48 $23,421 - $26,398	-1,289 Reduced 10.55%	10,931 $208,000
Q1 2023 May 11, 2023	BUY	$16.3 - $19.41 $9,339 - $11,121	573 Added 4.92%	12,220 $237,000
Q4 2022 Feb 13, 2023	BUY	$14.96 - $17.39 $177,964 - $206,871	11,896 Added 114.25%	22,308 $357,000
Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $159,488 - $185,394	-10,661 Reduced 47.79%	11,647 $186,000
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $1,473 - $2,093	-94 Reduced 0.89%	10,412 $154,000
Q2 2022 Aug 05, 2022	BUY	$17.44 - $23.16 $8,964 - $11,904	514 Added 5.14%	10,506 $208,000
Q1 2022 May 09, 2022	BUY	$17.03 - $22.67 $170,163 - $226,518	9,992 New	9,992 $228,000
Q2 2021 Aug 13, 2021	SELL	$17.95 - $25.56 $166,288 - $236,787	-9,264 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$20.53 - $25.22 $190,189 - $233,638	9,264 New	9,264 $210,000
Q4 2020 Feb 12, 2021	SELL	$18.39 - $24.8 $179,486 - $242,048	-9,760 Closed	0 $0
Q3 2020 Nov 06, 2020	SELL	$20.67 - $26.94 $23,935 - $31,196	-1,158 Reduced 10.61%	9,760 $239,000
Q2 2020 Jul 29, 2020	BUY	$16.46 - $27.42 $179,710 - $299,371	10,918 New	10,918 $259,000
Q4 2019 Feb 07, 2020	SELL	$15.15 - $18.89 $185,284 - $231,024	-12,230 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$17.68 - $22.65 $146,443 - $187,609	-8,283 Reduced 40.38%	12,230 $216,000
Q2 2019 Aug 12, 2019	SELL	$18.93 - $24.75 $330,233 - $431,763	-17,445 Reduced 45.96%	20,513 $438,000
Q1 2019 May 15, 2019	SELL	$19.6 - $24.76 $151,723 - $191,667	-7,741 Reduced 16.94%	37,958 $903,000
Q4 2018 Feb 01, 2019	BUY	$13.65 - $21.8 $175,579 - $280,413	12,863 Added 39.17%	45,699 $899,000
Q3 2018 Nov 09, 2018	SELL	$15.87 - $22.4 $79,556 - $112,291	-5,013 Reduced 13.24%	32,836 $582,000
Q2 2018 Aug 10, 2018	SELL	$18.56 - $22.45 $144,619 - $174,930	-7,792 Reduced 17.07%	37,849 $814,000
Q1 2018 May 04, 2018	SELL	$22.15 - $31.89 $179,880 - $258,978	-8,121 Reduced 15.11%	45,641 $1.01 Million
Q4 2017 Feb 06, 2018	SELL	$24.23 - $30.93 $37,847 - $48,312	-1,562 Reduced 2.82%	53,762 $1.63 Million
Q3 2017 Nov 13, 2017	BUY	$23.35 - $29.24 $54,172 - $67,836	2,320 Added 4.38%	55,324 $1.34 Million
Q2 2017 Aug 11, 2017	BUY	N/A	53,004	53,004 $1.31 Million

Others Institutions Holding EXEL

# of Institutions

501

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Account